The general objective of the Joint Action – Innovative Partnership for Action Against Cancer (iPAAC JA) is to develop innovative approaches to advances in cancer control. The innovation that will be covered within the JA consists of further development of cancer prevention, comprehensive approaches to the use of genomics in cancer control, cancer information and registries, improvements and challenges in cancer care, mapping of innovative cancer treatments and governance of integrated cancer control, including a new analysis of National Cancer Control Plans. The development of innovative approaches to cancer control will be supplemented by a Roadmap on Implementation and Sustainability of Cancer Control Actions, which will support Member States in implementation of iPAAC and CANCON recommendations. The Roadmap will act as the central pillar of the JA, integrating the diverse topic areas, providing synergies between the topics, ensuring consideration of transversal issues for all topics and acting as the central comprehensive deliverable, integrating all the JA outputs. A variety of methods will be used to fulfil the general and specific objectives including pilot studies, working groups, expert panels, literature review and surveys. A governmental board will be in place to ensure that implementation and sustainability in national contexts are duly considered for each topic area. The proposal for the iPAAC JA proposes actions to address objective 1 of the 2017 annual work programme, that is promoting health, preventing diseases and fostering supportive environments for healthy lifestyles taking into account the ‘health in all policies’ principle. The work to be developed by the iPAAC JA is complementary to the outcomes of the EPAAC and CANCON Joint Actions, funded by the Second and Third Health Programmes and will build on their outputs, using the stakeholder networks as an optimal base for the development of innovative cancer control actions.


The “Joint Action on integrating prevention, testing and link to care strategies across HIV, Viral Hepatitis, TB & STIs in Europe” (INTEGRATE) has the overall objective to increase Integrated early diagnosis and linkage to prevention and care of HIV, viral hepatitis, TB and STIs in EU Member States by 2020.
A number of tools have been developed to reduce transmission, optimize early diagnosis and linkage to care for one or more of these four diseases. INTEGRATE will map relevant existing tools for cross-linking. A peer-review process will identify which of these tools are complimentary or redundant for other disease(s), and which could be adapted or require further innovation.
HIV, viral hepatitis, TB and STIs are cross-borders public health threats of concern to Europe that affect vulnerable populations disproportionately and require personalised interventions. As multiple dimensional approaches are required to reduce the public health burden, the most optimal profile of approaches that provide additive effects (and that are reasonably cost-effective) should be identified and implemented broadly.
INTEGRATE provides a platform to disseminate and exchange best practice among Member States and facilitate discussions on innovations and emerging issues within the four diseases. In this respect, INTEGRATE is a shared European effort that extends beyond the partners and can create important synergies across European stakeholders, projects and initiatives.
INTEGRATE supports the implementation of the Commission Communication on ‘Combating HIV/AIDS in the European Union and neighboring countries’ and the ‘Action Plan on HIV/AIDS in the EU and neighboring countries’ by ensuring better preparedness across the EU and by identifying innovative evidence-based testing and prevention tools to reduce new cases of HIV, viral hepatitis, TB and STIs in priority groups.


This Joint Action on Rare Cancers (JARC) will be aimed at:

1. prioritising rare cancers (RCs) in the agenda of the Europe (EU) and Member States;
2. developing innovative and shared solutions for European Reference Networks (ERNs) on RCs, in the areas of quality of care, innovation, education and state of the art definition on prevention, diagnosis and treatment.
The objectives of JARC will be achieved by creating a platform for competent national authorities as well as institutions, scientific and professional societies and patient organisations, to produce consensus-based recommendations, with a special view to the new ERNs, seen as a great opportunity for improvement of RC patient outcomes in the EU.
Following the results of the RARECARE project, all the 12 families of RCs will be considered. Consensus-based recommendations about RCs will be provided to improve: 1) epidemiological surveillance of RCs; 2) quality of healthcare, primarily through the new ERNs; 3) the availability of clinical practice guidelines on RCs; 4) innovation, also by optimizing clinical research regulations as well as practices and semantics regarding patient data and tissues; 5) medical and patient education; 6) health policy measures on RCs at the EU and national level; 7) patient empowerment (which will be pursued across all items dealt with by JARC). All EU stakeholders in the field of RCs and rare diseases will be involved.
JARC will carry forward the aims of the Third Health Programme by improving chances of EU RC patients to have access to appropriate healthcare, primarily through optimal shaping of ERNs. Thus, all this should result in reduced healthcare inequalities, increased innovation in health, increased sustainability of health systems, decreased health migration and reduction of gaps in rare cancers survival across EU countries.



For many years tobacco consumption has been considered the single most important cause of preventable morbidity wordwide. Efforts to reduce the devastation of tobacco related death and illness in the EU, consist of the Tobacco Products Directive (TPD), the Tobacco Advertising Directive (TAD) and the Framework Convention on Tobacco Control (FCTC) from WHO.
The general objective of the Joint Action on Tobacco Control 2 will be to provide support of the implementation of TPD and TAD.
The specific objectives of the program are:
1. To ensure appropriate coordination and evaluation
2. To support dissemination of information to the target groups
3. To integrate the JATC results into national policies
4. To facilitate the exchange of good practices between Member States in order to improve implementation of the Tobacco Products Directive (TPD) and related implementing and delegated acts in a number of areas of tobacco product and e-cigarette regulation, including laboratory capacity, analysis and assessment.
5. To ensure greater consistency in the application of the TPD to ensure a fair internal market for tobacco and related products, especially regarding market surveillance and enforcement.
6. Promote activities consistent with the objectives of the WHO Framework Convention on Tobacco Control.
7. To identify and assess the current legislation regarding, but not exclusively tobacco advertising and advertising of emerging products.
8. To identify and develop best practices regarding tobacco endgame strategies and for smoke-free environments.
As more and more countries step up in the game of tobacco control and prevention against tobacco related cancer, a unified Europe is more important than ever. The commitment is also showed in the approaching new EU Cancer Action Plan, where EU MS will stand together in the fight against tobacco. We, the partners of the JATC 2, are commited to championing this fight.


Smoking and other forms of tobacco consumption are considered the single most important cause of preventable morbidity and premature mortality worldwide. Efforts to reduce the devastation of tobacco-related deaths and illness in the EU consist of the Tobacco Products Directive (TPD), and the WHO Framework Convention on Tobacco Control (FCTC). The TPD lays down rules governing the manufacture, presentation and sale of tobacco and related products. The TPD stipulates that Member States shall require manufacturers and importers of tobacco products to submit to their competent authorities information, via a common entry gate (EU-CEG) – an IT tool designed to ensure uniform application of the reporting and notification obligations, harmonise the submission of data, facilitate comparison and reduce administrative burden.

The general objective of the Joint Action on Tobacco Control will be to provide support for the implementation of the TPD throughout the 28 EU MS through the mining of EU-CEG data, supporting of laboratory collaborations and effort to evaluate priority additives. The specific aims of the project are:

• To ensure appropriate coordination and evaluation
• To support the dissemination of information to the public, regulators and researchers.
• To enhance the ease of access to the data collected through the EU CEG
• To monitor and provide support to the tasks of tobacco and e-cigarette product regulation
• Assist EU MS networking and collaborations between laboratories for tobacco evaluation.
• Support EU MS in the process of monitoring and updating priority additives
• To integrate the JATC results into national policies

With the above in mind, this proposal comes at a perfect timing to aid the regulatory activities that would be needed across the EU MS with regards to the implementation of the TPD across 28 EU MS spanning a population of 508 Million people.
